Surufatinib after surgery for high-risk neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a pill called surufatinib after surgery to see if it can prevent neuroendocrine tumors from coming back. It is for patients with high-risk features like advanced stage or a higher grade of tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had surgery to remove a neuroendocrine tumor that was stage III, grade G1/G2, or any grade G3 according to the AJCC staging system.
- Your doctor determines you have high-risk factors for the tumor coming back.
- Your organs (like bone marrow, liver, and kidneys) are working well based on recent blood tests.
- You have not had a major surgery or serious injury in the past month.
- If you can become pregnant or father a child, you must use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called surufatinib for people with neuroendocrine tumors. It aims to see how safe and effective the treatment is in real-world patients.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
Hear when a new Neuroendocrine Neoplasms (Tumours) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.